SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Illumina, Inc. – ‘8-K’ for 2/4/21

On:  Friday, 2/5/21, at 8:30am ET   ·   For:  2/4/21   ·   Accession #:  950157-21-121   ·   File #:  1-35406

Previous ‘8-K’:  ‘8-K’ on 1/12/21 for 1/11/21   ·   Next:  ‘8-K’ on / for 2/11/21   ·   Latest:  ‘8-K’ on / for 4/12/24   ·   14 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/05/21  Illumina, Inc.                    8-K:1,9     2/04/21   11:202K                                   Cravath Swaine & … 01/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     33K 
 2: EX-2.1      Amendment, Dated as of February 4, 2021, to the     HTML     25K 
                Agreement and Plan of Merger                                     
 7: R1          Document and Entity Information                     HTML     46K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 6: XML         XBRL Instance -- form8-k_htm                         XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- ilmn-20210204_lab                     XML     64K 
 5: EX-101.PRE  XBRL Presentations -- ilmn-20210204_pre              XML     46K 
 3: EX-101.SCH  XBRL Schema -- ilmn-20210204                         XSD     15K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               13±    20K 
11: ZIP         XBRL Zipped Folder -- 0000950157-21-000121-xbrl      Zip     19K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C: 
 i false i 000111080300011108032021-02-042021-02-04




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



Form  i 8-K



Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i February 4, 2021



graphic



 i Illumina, Inc.
(Exact name of registrant as specified in its charter)

 i 001-35406
(Commission File Number)

 i Delaware
(State or other jurisdiction of incorporation)
 
 i 33-0804655
(I.R.S. Employer Identification No.)

 i 5200 Illumina Way,  i San Diego,  i CA  i 92122
(Address of principal executive offices) (Zip code)

( i 858)  i 202-4500
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 i 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 i Common Stock, $0.01 par value
Trading Symbol(s)
 i ILMN
Name of each exchange on which registered
 i The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. ☐





Item 1.01.          Entry into a Material Definitive Agreement.

Amendment to Merger Agreement

On February 4, 2021, Illumina, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Agreement and Plan of Merger (the “Merger Agreement”), dated September 20, 2020, among the Company, SDG Ops, Inc., a Delaware corporation and direct, wholly owned subsidiary of Parent, SDG Ops, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Parent, and GRAIL, Inc., a Delaware corporation (“GRAIL”).

The Amendment provides that any required tax withholdings with respect to any portion of the merger consideration to be paid pursuant to the Merger Agreement to holders of GRAIL equity awards in respect of such awards in the form of shares of common stock, par value $0.01 per share of the Company (“Company Common Stock”), will be satisfied by “net settlement”, whereby the Company will retain a portion of any such shares of Company Common Stock with a value equal to any such required tax withholdings.  All other required withholdings and deductions with respect to the merger consideration to be received pursuant to the Merger Agreement by any holder of GRAIL equity awards in respect of such awards will continue to be satisfied by reducing the cash portion of such consideration, unless the amount of such withholdings and deductions exceeds the cash portion, in which case the Company will retain an additional portion of the shares of Company Common Stock to be received by such holder with a value equal to such excess.

The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by the full text of the Amendment, which is attached hereto as Exhibit 2.1 and is incorporated by reference herein.


Additional Information and Where to Find It

In connection with the proposed transaction, the Company filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus with respect to the Company’s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL in connection with the proposed transaction.  The Company may also file other documents with the SEC regarding the proposed transaction.  This document is not a substitute for the consent solicitation statement/prospectus or the Registration Statement or any other document which the Company may file with the SEC.  INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH INCLUDES THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS.  Investors and security holders may obtain free copies of the Registration Statement, which includes the consent solicitation statement/prospectus, and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov, through the Company’s Investor Relations page (investor.illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122.

No Offer or Solicitation

This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.





Cautionary Notes on Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target,” similar expressions and variations or negatives of these words.  Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof.  These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all.  Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the Company’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of the Company’s common stock and on the Company’s operating results, (vi) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (vii) the risks and costs associated with the integration of, and the ability of the Company to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (viii) the risks and costs associated with the development and commercialization of, and the Company’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in the consent solicitation statement/prospectus that is included in the Registration Statement, as well as in the Company’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors.

These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the consent solicitation statement/prospectus that is included in the Registration Statement.  While the list of factors presented here is, and the list of factors  presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties.  Unlisted factors may present significant additional obstacles to the realization of forward-looking statements.  Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the Company’s financial condition, results of operations, credit rating or liquidity.  The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.


Item 9.01.
Exhibits.
 
Exhibit Number
 
Description of Exhibit
 
 
 
 
104
 
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: February 5, 2021

  ILLUMINA, INC.
 
       
       

By:
/s/ Charles E. Dadswell  
    Name: Charles E. Dadswell  
    Title: Senior Vice President, General Counsel and Secretary  
       




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:2/5/214,  425,  CORRESP,  S-4/A
For Period end:2/4/21
9/20/208-K
9/17/204
9/9/20
 List all Filings 


14 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/16/24  Illumina, Inc.                    10-K       12/31/23  111:18M
 2/17/23  Illumina, Inc.                    10-K        1/01/23  108:17M
12/01/22  Illumina, Inc.                    424B2                  2:533K                                   Donnelley … Solutions/FA
11/29/22  Illumina, Inc.                    424B2                  1:500K                                   Donnelley … Solutions/FA
 5/02/22  Illumina, Inc.                    8-A12G                 1:17K                                    Cravath Swaine & … 01/FA
 2/18/22  Illumina, Inc.                    10-K        1/02/22  108:15M
11/15/21  Illumina, Inc.                    SC TO-I                4:655K Illumina, Inc.                    Donnelley … Solutions/FA
 8/18/21  Illumina, Inc.                    8-K:1,2,8,9 8/18/21   12:686K                                   Cravath Swaine & … 01/FA
 3/17/21  Illumina, Inc.                    424B2                  1:501K                                   Donnelley … Solutions/FA
 3/16/21  Illumina, Inc.                    424B2                  1:487K                                   Donnelley … Solutions/FA
 3/12/21  Illumina, Inc.                    S-3ASR      3/12/21    5:694K                                   Donnelley … Solutions/FA
 2/17/21  Illumina, Inc.                    10-K        1/03/21  102:13M
 2/09/21  Illumina, Inc.                    424B3                  1:4.8M                                   Donnelley … Solutions/FA
 2/05/21  Illumina, Inc.                    S-4/A                  7:5M                                     Donnelley … Solutions/FA
Top
Filing Submission 0000950157-21-000121   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 7:03:00.2pm ET